Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
48 results about "Cotinine" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cotinine is an alkaloid found in tobacco and is also the predominant metabolite of nicotine. Cotinine is used as a biomarker for exposure to tobacco smoke. Cotinine is currently being studied as a treatment for depression, PTSD, schizophrenia, Alzheimer's disease and Parkinson's disease. Cotinine was developed as an antidepressant as a fumaric acid salt, cotinine fumarate, to be sold under the brand name Scotine but it was never marketed.
Chewing tobacco substitute containing cotinine
The invention is a chewing tobacco substitute made from natural leaves and additives which simulate the taste and consistency of chewing tobacco to which a nicotine compound is added. The invention allows those addicted to chewing tobacco to chew and receive nicotine without incurring the other harmful side effects of tobacco. In one embodiment of the invention the product is provided with varying levels of nicotine.
Owner:WHALEN WILLIAM
Synchronous analysis method for trace nicotine in blood-brain samples of animal and main metabolites thereof
InactiveCN104020241ADirectly and accurately measureEasy to operateComponent separationDialysate sampleAnimal science
The invention discloses a synchronous analysis method for trace nicotine in blood-brain samples of an animal and main metabolites thereof. The synchronous analysis method is characterized by comprising the following steps of: utilizing a microdialysis system to synchronously collect blood dialysate and brain tissue dialysate samples of an animal in lined pipes of different chromatographic sampling bottles, respectively adding NIC-d3 and COT-d3 to be mixed with internal labeled solution, and after mixing uniformly, directly analyzing and detecting the content of the nicotine and cotinine in a microdialysis sample by using UPLC-MS / MS. The synchronous analysis method disclosed by the invention has the advantages that the pretreatment steps of protein precipitation and purification for the samples are not needed, the synchronous and accurate analysis of nicotine and metabolites in an animal body is realized; and compared with the prior art, the synchronous analysis method has the characteristics of simple operation, high sensitivity and reliable result and the like, and a new method for researching the metabolism of the nicotine in the animal body is provided.
Owner:ZHENGZHOU TOBACCO RES INST OF CNTC
Cotinine neutralizing antibody
ActiveUS8008448B2Inhibition is effectiveBinding of B3 clone to cotinine BSA is reducedNervous disorderHybrid immunoglobulinsCotinineMonoclonal antibody
Owner:NAT CANCER CENT
Burley tobacco nicotine extract product and extraction technology for same
The invention provides a burley tobacco nicotine extract product and an extraction technology for the same. The burley tobacco nicotine extract product is composed of the following components according to weight by percentage: 94 to 97% of nicotine, 0.4 to 0.6% of cotinine, 0.2 to 0.3% of N-methy pridine carboxamide, 0.1 to 0.2% of benzofuran, 0.1 to 0.2% of indol, 0.1 to 0.2% of 5.5-dimethyle pyrazoline, 0.05 to 0.15% of acetyl pridine, 0.05 to 0.1% of megastigmatrienone, 0.02 to 0.05% of hydroxide radical damascenone, 0.02 to 0.05% of palmitic acid and 0.01 to 0.04% of demethylation nicotine. The burley tobacco nicotine extract product has nigh nicotine content and has special flavor when prepared for electronic tobacco juice; electronic cigarette satisfaction can be enhanced; and the electronic cigarette can be closer to cigarette taste.
Owner:CHINA TOBACCO HUNAN INDAL CORP
Novel bacterial strain for nicotine degradation-Pseudomonas ZUTSKD and uses thereof
The invention provides a new nicotine-degrading bacteria-pseudomonas ZUTSKD and its application. The ZUTSKD (Pseudomonas sp.ZUTSKD) is stored in China Center for Type Culture Collection, the storing date was June 18th, 2007, the preservation no. is CCTCC NO:M 207083. The bacteria can degrade nicotine and generate such intermediate as 2, 3'-Bipyridine, cotinine, 3-(3, 4-dihydro-2H-pyrrol-5-y1)-Pyridine and 3-Pyridinecarboxylic acid, the max. nicotine concentration withstandable is 5.5 g / L. The invention can reduce the nicotine in waste cigarette residues, and is of certain application prospect in the industry.
Owner:ZHEJIANG UNIV OF TECH
Flue-cured tobacco nicotine extract product and extraction technology
The invention provides a flue-cured tobacco nicotine extract product and an extraction technology. The flue-cured tobacco nicotine extract product comprises the following components according to weight by percentage: 92 to 96% of nicotine, 0.5 to 1% of cotinine, 0.2 to 0.8% of 2,3-dhydro-3,5-dyhydroxy,6-methyl-4H-prone, 0.2 to 0.5% of hydroxymethylfurfural, 0.1 to 0.4% of 3-hydroxy-Beta-damascenone, 0.1 to 0.3% of megastigmatrienone, 0.1 to 0.3% of methyl heptenone, 0.1 to 0.2% of palmitic acid, and 0.05 to 0.1% of demethylation. The flue-cured tobacco nicotine extract product has high nicotine content, when prepared into electronic tobacco juice, has special flavor; and satisfaction of the electronic cigarette can be met, so the electronic cigarette can be closer to cigarette flavors.
Owner:CHINA TOBACCO HUNAN INDAL CORP
Multi-portion intra-oral dosage form with organoleptic properties
InactiveCN101843581ASolve the serious problem of high first-pass effectOrganic active ingredientsNervous disorderNornicotineActive agent
The present invention relates to a multi portion intra-oral dosage form comprising at least one pharmaceutically active agent or health promoting agent wherein at least one portion comprises a component for creating a noticeable organoleptic sensation. Of certain interest is use of sensory markers / signals as conceptual aids for a subject using the dosage form whereby the organoleptic sensation / s is / are such that it / they facilitate / s for the subject to identify a portion and differentiate between different portions thereof. Also contemplated are a dosage form, a method and a system for delivering active agents, such as nicotine and / or metabolites thereof, such as cotinine, nicotine N'-oxide, nornicotine, (S)-nicotine-N--glucuronide and mixtures, isomers, salts and complexes thereof as well as use and production of said dosage forms.
Owner:MCNEIL AB
Application of melatonin in preparation of medicine for improving oocyte quality
InactiveCN110833542AAffect qualityImprove reproductive abilityOrganic active ingredientsSexual disorderCotininePhysiology
The invention discloses an application of melatonin in preparation of a medicine for improving oocyte quality. According to the invention, melatonin is directly added into an oocyte in-vitro maturation culture solution, which proves that the melatonin can relieve the reduction of the quality of the cotinine-induced oocytes and is shown as reduction of the ROS level in the oocytes, reduction of aneuploidy formation, promotion of uniform distribution of actin, improvement of the form of spindles and improvement of mitochondrial functions, and then the later fertilization rate of the oocytes is remarkably increased. The invention provides a method for improving the influence of the main metabolite cotinine of nicotine in the blood of a smoker on the quality of female oocytes, and provides aneffective method for improving the reproductive capacity of smoking women.
Owner:NANTONG UNIVERSITY
Chimeric antigen receptor to which Anti-cotinine antibody is linked, and use thereof
ActiveUS20180256744A1Induce cell deathSuppress adverse immune side effectOrganic active ingredientsPeptide/protein ingredientsAntigenCotinine
The present invention relates to chimeric antibody receptors with anti-cotinine antibodies linked, and use thereof. A T cell presenting the chimeric antibody receptor on the surface secretes interferon gamma specifically for a target molecule of a cotinine-conjugated binding molecule that is added together therewith and induces cell death of the cell expressing the target molecule by the T cell. On the contrary, by administering a cytotoxic agent conjugated with cotinine, cell death of the chimeric antigen receptor T cell is induced. Therefore, if necessary, a cytotoxic agent conjugated with cotinine can be administered to remove the chimeric antigen receptor T cells that have been already administered, thereby suppressing immune side effects due to hyperactivity of T cells. Thus, the chimeric antigen receptor to which the anti-cotinine antibody is linked can be effectively and safely used for the treatment of cancer.
Owner:SEOUL NAT UNIV R&DB FOUND
Method for evaluating influences of smoking on quality of oocytes
The invention discloses a method for evaluating the influences of smoking on the quality of oocytes. Specifically, oocytes are cultured to be mature in culture solutions containing different concentrations of cotinine. Finally, the influences of smoking on the quality of oocytes are evaluated by detecting some indicators, such as the maturation rate of oocytes, chromosomal aneuploidy, actin distribution, mitochondrial membrane potential, intracellular reactive oxygen species level, spindle morphology, chromosome arrangement of mature oocytes, sperm binding number after in-vitro fertilization,pronucleus formation rate after parthenogenetic activation and the like. Through a large number of objective tests, the influences of smoking on the quality of oocytes are evaluated, thus providing areference of theoretical data for the maintenance of reproductive capacity of female smokers.
Owner:NANTONG UNIVERSITY
High-sensitivity and high-accuracy method for simultaneously determining NNAL and cotinine in urine
ActiveCN110333308ASolve processingTime-consuming to solveComponent separationIsotopeSolid phase extraction
The invention discloses a high-sensitivity and high-accuracy method for simultaneously determining NNAL and cotinine in urine. The method comprises the following steps: 1) preparing a single standardstock solution containing the NNAL, the cotinine, isotope-labeled NNAL and isotope-labeled cotinine; 2) preparing mixed standard sample working solutions having a series of concentrations and containing the NNAL and the cotinine, and making a standard curve; 3) taking a to-be-determined urine sample, adding a phosphate buffer solution containing an isotope-labeled internal standard, and adding 15-25 [mu]L of beta-glucuronidase for enzymolysis; and 4) taking out the sample solution subjected to the enzymolysis, naturally cooling the sample solution into the room temperature, performing solid-phase extraction, performing instrument analysis, and performing calculation according to the standard curve made in the step 2) to obtain the content of the NNAL and the cotinine. The method effectively solves the problems of complex pretreatment and long consumed time of an existing method for simultaneously testing the NNAL and the cotinine in the urine; and meanwhile, the matrix effect in the urine is greatly reduced, so that the detection sensitivity and accuracy are improved.
Owner:SICHUAN UNIV
Population size survey method based on sewage concentration monitoring
The invention discloses a population size survey method based on sewage concentration monitoring. The method specifically comprises the following steps of S1, determining a region where a pre-estimated popularization size is located, selecting a sewage treatment plant of the region, and collecting water inflow samples of the sewage treatment plant for pretreatment of the samples; S2, selecting a human metabolite of ammonia nitrogen and a tobacco metabolite of cotinine as biomarkers; S3 , measuring the concentration of ammonia nitrogen in measurement sewage by use of a national standard method,wherein the national standard method specifies that the concentration of ammonia nitrogen in measurement sewage is measured by use of a Nessler's Reagent spectrophotometric method; S4, measuring theconcentration of cotinine by use of a liquid chromatography-mass spectrometer or a gas chromatograph-mass spectrometer; and S5, calculating output per capita of the two biomarkers, and calculating bya biomarker method to obtain the popularization size of the region where the sewage treatment plant is located.
Owner:DALIAN MARITIME UNIVERSITY
Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation
Owner:UNIV OF SOUTH FLORIDA +1
Nicotine replacement therapy products comprising synthetic nicotine
A composition suitable for use in nicotine replacement therapy products includes a nicotine product that includes a synthetic nicotine that is substantially free of one or more contaminants and / or impurities normally associated with tobacco-derived nicotine. For example, the synthetic nicotine is substantially free of one or more of nicotine-1'-N-oxide, nicotyrine, nornicotyrine, 2',3-bipyridyl, cotinine, anabasine, and / or anatabine. The composition further comprises one or more pharmaceutically acceptable excipients, additives and / or carriers. The nicotine replacement therapy products may include any number of such products, including transdermal nicotine delivery patches, nicotine gums, synthetic chewing tobacco, synthetic snuff, and synthetic strips (e.g., dissolvable synthetic tobacco). Additionally, a method of treating nicotine addiction includes administering a nicotine replacement composition, e.g., via a nicotine replacement therapy product, to a user.
Owner:NEXT GENERATION LABS LLC
Nicotine composition for vaping devices and vaping devices employing the same
A composition suitable for use in a vaping device includes a nicotine product that includes a synthetic nicotine that is substantially free of one or more contaminants and / or impurities normally associated with tobacco-derived nicotine. For example, the synthetic nicotine is substantially free of one or more of nicotine-1'- N-oxide, nicotyrine, nornicotyrine, 2',3-bipyridyl, cotinine, anabasine, and / or anatabine. The composition further comprises one or more pharmaceutically acceptable excipients, additives and / or solvents.
Owner:NEXT GENERATION LABS LLC
The combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological conditions
ActiveUS20200000790A1Reduce consolidationImprove extinctionOrganic active ingredientsNervous disorderContextual fearCotinine
The present invention relates to a method of a) treating any of depression induced by chronic stress; depression in a subject afflicted with PTSD; anxiety induced by chronic stress; anxiety in a subject afflicted with PTSD; cognitive impairment induced by chronic stress; altered morphology and / or reduced number of GFAP+ cells in hippocampus and / or frontal cortex induced by chronic stress; working memory impairment in a subject afflicted with PTSD; b) inhibiting or reversing loss of GFAP+ cells in hippocampus and / or frontal cortex induced by chronic stress; c) decreasing consolidation of contextual fear memory in a subject afflicted with PTSD; d) enhancing extinction of fear memory in a subject afflicted with PTSD; or e) increasing calcineurin A expression in a subject afflicted with PTSD using a combination of cotinine and an antioxidant.
Owner:U S GOVERNMENT REPRESENTED BY THE DEPT OF VETERANS AFFAIRS +1
Anti-her2 affibody, and switchable chimeric antigen receptor using same as switch molecule
PendingCN113825772APolypeptide with localisation/targeting motifOrganic active ingredientsAntigen receptorCotinine
Owner:ABCLON
Chewing gum composition for eliminating nicotine
InactiveUS20030129145A1Soften physical propertyImprove stabilityBiocideOrganic active ingredientsUrine cotinine levelChewing gum
Disclosed is a chewing gum composition capable of eliminating nicotine component from the body of a person chewing the chewing gum. Such a chewing gum composition functions to convert the nicotine produced in a human body after smoking to cotinine and to discharge the cotinine into urine. Accordingly, by chewing the chewing gum of the present invention, not only nicotine can be eliminated from the body, but also the incidence of cancer due to nicotine can be largely reduced.
Owner:TONG YANG CONFECTIONERY
Rose flavor smearing cigarette and preparing method thereof
InactiveCN106723299AIncrease the effective surface areaPromote absorptionTobacco treatmentFlavorCombustion
Owner:GUANGDONG BRANCH OF CHINA TOBACCO GENERAL
Diagnostic test for distinguishing the smoking status of a subject
ActiveUS20200141933A1Increase powerRapid and cost-effective and easy to useMaterial analysis by observing effect on chemical indicatorBiological testingCotinineDiagnostic test
There is disclosed herein a device for determining the smoking status of a subject, wherein said device comprises a plurality of different specific binding molecules deposited to a solid phase to detect specifically the presence of two or three tobacco smoke exposure biomarkers in a biological sample, said biomarkers consisting of: (i) cotinine and total 4-(methylnitrosamino)-1-(3-, pyridyl)-1-butanol (NNAL); (ii) cotinine and N-acetyl-S-[2-carboxyethyl]-L-cysteine (CEMA); or (iii) cotinine and NNAL and CEMA.
Owner:PHILIP MORRIS PROD SA
Natural killer cell expressing Anti-cotinine chimeric antigen receptor
ActiveUS20190365815A1Improve efficiencyEffective movementPolypeptide with localisation/targeting motifImmunoglobulin superfamilyCotinineAntigen receptors
Disclosed are a natural killer (NK) cell expressing an anti-cotinine chimeric antigen receptor (CAR) specifically binding to cotinine, and a cell therapeutic agent containing the NK cell. The CAR-expressing NK cell which specifically binds cotinine, can effectively move to tumor tissue, regardless of the kind of cancer, depending on the binding substance bound to cotinine. Therefore, the natural killer cell can be usefully employed as a gene therapy exhibiting a highly efficient anticancer effect.
Owner:KOREA RES INST OF BIOSCI & BIOTECH +1
Cigarette with mint flavor and preparation method thereof
InactiveCN106923373AIncrease the effective surface areaPromote absorptionTobacco treatmentNicotiana tabacumPropolis
The invention belongs to the field of cigarette products and discloses a cigarette with a mint flavor and a preparation method thereof. The cigarette with a mint flavor is made up of following ingredients such as paraffin, vaseline, propolis, nicotine, cotinine, neodiphene, furfural, violet alcohol, mezotone, geranyl acetone, catechol, dalcate, geranene, preservatives, sodium glycocholate, 5-hydroxymethyl furfural, ionone, purple yellow, mint flavor, the amount of pH regulators and the rest of stearic acid. The pH of the cigarette with a mint flavor ranges from 5.0 to 5.5. The cigarette with a mint flavor is used as a substitute for a conventional citrate and has the flavor, vigor and taste similar to the conventional one. The cigarette is convenient to carry and helps avoid fire disasters without combustion. People are not affected by smoke. Second-hand smoke is avoided. The cigratte has a broad application scope.
Owner:GUANGDONG BRANCH OF CHINA TOBACCO GENERAL
Use of cotinine in treating or preventing neurogenesis deficits and enhancing neurogenesis
ActiveUS20170296525A1Reduce expressionReduce negative impactNervous disorderHeterocyclic compound active ingredientsCotinineNeurogenesis
A method of inhibiting or treating chemotherapy-induced cognitive dysfunction comprising administering a therapeutically effective amount of cotinine to a cancer patient experiencing chemotherapy-induced cognitive dysfunction.
Owner:UNIV OF SOUTH FLORIDA +1
Ovulation detection test strip and detection method
PendingCN112730854AHigh detection sensitivityStrong specificityBiological testingAntiendomysial antibodiesCotinine
The invention discloses an ovulation detection test strip. The ovulation detection test strip comprises a PVC bottom plate, a sample pad, a gold label pad, a nitrocellulose film and a water absorption pad, wherein the nitrocellulose film is provided with a detection line T1, a detection line T2 and a quality control line, the detection line T1 is coated with a mouse anti-human beta LH monoclonal antibody 1A4, the detection line T2 is coated with a cotinine antigen, and the quality control line is coated with a goat anti-chicken IgY polyclonal antibody; and a colloidal gold mouse anti-human beta LH monoclonal antibody 6B8 conjugate, a colloidal gold chicken IgY antibody conjugate and a colloidal gold cotinine monoclonal antibody conjugate are cured on the gold label pad. The test strip is high in detection sensitivity and good in specificity, abnormal interpretation results caused by crossing of LH with follicle stimulating hormone (FSH) and thyroid stimulating hormone (TSH) can be avoided, detection results are more accurate, and monitoring of the smoking metabolite cotinine in urine is combined. The invention further discloses an ovulation detection method, the steps are simple, and the test result is accurate.
Owner:杭州新脉生物科技有限公司
A kind of analysis method of nicotine and cotinine in urine
ActiveCN108548878BRealize online analysisMeet analysis needsComponent separationCotinineInternal standard
Owner:SHANGHAI TOBACCO GRP CO LTD
Natural killer cell expressing anti-cotinine chimeric antigen receptor
ActiveCN110475857AEffective movementHighly effective anticancer effectPeptide/protein ingredientsAntibody mimetics/scaffoldsAntigenCotinine
Owner:KOREA RES INST OF BIOSCI & BIOTECH +1
Complex in which anti-cotinine antibody is bound to conjugate of cotinine and binding substance, and use thereof
ActiveUS9867886B2Prolong half-life in vivoHormone peptidesOrganic active ingredientsCotinineHalf-life
Owner:SEOUL NAT UNIV R&DB FOUND
A method for simultaneously measuring the contents of nicotine, 3-(pyrrolidin-2-yl)pyridine, pyridylpyrrolidone and testosterone in serum
ActiveCN110146615BMeet trace analysis needsHigh detection sensitivityComponent separationCotinineFluid phase
Owner:WENZHOU VOCATIONAL COLLEGE OF SCI & TECH
Systems and methods for combined vertical/lateral flow blood separation technologies with cotinine detection
Owner:POLYMER TECH SYST
Antibody-drug composite platform using bispecific antibody
PendingCN109414509AExtended half-lifeGood antitumor activityAntibody ingredientsImmunoglobulinsCotinineHalf-life
The present invention relates to an antibody-drug composite using a bispecific antibody and a use thereof. According to the antibody-drug composite of the present invention, a composite of an antibodyand a drug can be easily formed by a binding of a conjugate of a bivalent cotinine-peptide and a drug and an anti-cotinine single chain variable fragment without the need of a multi-step synthesis procedure In addition, the antibody-drug composite of the present invention can effectively deliver the drug to a target to which the antibody specifically binds, and can improve the therapeutic effectby increasing the half-life of the drug in the body.
Owner:SEOUL NAT UNIV R&DB FOUND
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com